Please use this identifier to cite or link to this item: https://doi.org/10.1002/hep.22414
Title: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
Authors: Marcellin, P.
Chang, T.-T.
Lee Lim, S.G. 
Sievert, W.
Tong, M.
Arterburn, S.
Borroto-Esoda, K.
Frederick, D.
Rousseau, F.
Issue Date: Sep-2008
Citation: Marcellin, P., Chang, T.-T., Lee Lim, S.G., Sievert, W., Tong, M., Arterburn, S., Borroto-Esoda, K., Frederick, D., Rousseau, F. (2008-09). Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48 (3) : 750-758. ScholarBank@NUS Repository. https://doi.org/10.1002/hep.22414
Abstract: Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared with placebo. The long-term efficacy and safety of ADV in a subset of these patients was investigated for up to 5 years. Sixty-five patients given ADV 10 mg in year 1 elected to continue in a long-term safety and efficacy study (LTSES). At enrollment, the 65 LTSES patients were a median 34 years old, 83% male, 74% Asian, 23% Caucasian, median baseline serum hepatitis B virus (HBV) DNA 8.45 log10 copies/mL, and median baseline alanine aminotransferase (ALT) 2.0 x upper limit of normal. At 5 years on study, the median changes from baseline in serum HBV DNA and ALT for the 41 patients still on ADV were 4.05 log10 copies/mL and - 50 U/L, respectively. HBeAg loss and seroconversion were observed in 58% and 48% of patients by end of study, respectively. Fifteen patients had baseline and end of follow-up liver biopsies; improvements in necroinflammation and fibrosis were seen in 67% and 60% of these patients, respectively. Adefovir resistance mutations A181V or N236T developed in 13 LTSES patients; the first observation was at study week 195. There were no serious adverse events related to ADV. Conclusion: Treatment with ADV beyond 48 weeks was well tolerated and produced long-term virological, biochemical, serological, and histological improvement. Copyright © 2008 by the American Association for the Study of Liver Diseases.
Source Title: Hepatology
URI: http://scholarbank.nus.edu.sg/handle/10635/132798
ISSN: 02709139
DOI: 10.1002/hep.22414
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

232
checked on Jul 18, 2018

WEB OF SCIENCETM
Citations

193
checked on Jun 4, 2018

Page view(s)

9
checked on Jun 28, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.